Table 1.
Baseline characteristics of 1365 persons with DM included in the registry
| Total | T1DM | T2DM | Other forms of DM | |
| Number (%) | 1365 (100) | 1054 (77.2) | 223 (16.3) | 88 (6.5) |
| Age, years | 46.1 (16.1) | 42.8 (15.5) | 59.9 (10.8) | 52.6 (11.6) |
| Male gender, n (%) | 744 (54.5) | 555 (52.7) | 142 (63.7) | 30 (48.4) |
| Therapy | ||||
| Insulin monotherapy | 1131 (82.9) | 100 (100.0) | 88 (39.5) | 45 (72.6) |
| Insulin and OBGLD | 234 (17.1) | 63 (5.9) | 130 (5.8) | 17 (19.3) |
| Presence of microvascular complications | ||||
| Neuropathy, n (%) | 230 (16.8) | 154 (14.6) | 23 (10.3) | 6 (9.7) |
| Albuminuria, n (%) | 244 (17.9) | 180 (17.1) | 50 (22.4) | 10 (16.1) |
| Retinopathy, n (%) | 247 (18.1) | 199 (18.9) | 39 (17.5) | 6 (9.7) |
| Presence of cardiovascular disease | ||||
| Angina pectoris, n (%) | 33 (2.4) | 15 (1.4) | 14 (6.3) | 2 (3.2) |
| PCI, n (%) | 52 (3.8) | 31 (2.9) | 14 (6.3) | 4 (6.5) |
| Myocardial infarction, n (%) | 40 (2.9) | 23 (2.2) | 14 (6.3) | 2 (3.2) |
| CABG, n (%) | 37 (2.7) | 23 (2.2) | 11 (4.9) | 2 (3.2) |
| TIA, n (%) | 28 (2.1) | 14 (1.3) | 9 (4.0) | 3 (4.8) |
| CVA, n (%) | 23 (1.7) | 14 (1.3) | 6 (2.7) | 3 (4.8) |
| Peripheral arterial disease, n (%) | 51 (3.7) | 29 (2.8) | 18 (8.1) | 2 (3.2) |
| Indication for FSL-FGM use | ||||
| Hypoglycemia unawareness 1 | 156 (11.4) | 119 (11.3) | 25 (11.2) | 8 (12.9) |
| Unexpected hypoglycemias 2 | 410 (30.0) | 322 (30.6) | 56 (25.1) | 25 (40.3) |
| HbA1c>70 mmol/mol (8.5%) 3 | 294 (21.5) | 202 (19.2) | 80 (35.9) | 6 (9.7) |
| Unwanted sensation loss of the fingers 4 | 19 (1.4) | 14 (1.3) | 5 (2.2) | 0 (0.0) |
| Occupational hazards with hypoglycemia 5 | 57 (4.2) | 39 (3.7) | 11 (4.9) | 4 (6.5) |
| Individuals eligible for CGM 6 | 45 (3.3) | 40 (3.8) | 2 (0.9) | 2 (3.2) |
| Individuals already using FSL-FGM 7 | 100 (7.3) | 76 (7.2) | 14 (6.3) | 6 (9.7) |
| Multiple indications | 284 (20.8) | 242 (23.0) | 30 (13.5) | 11 (17.7) |
Data are presented as numbers (%), means (SD) or medians (25th, 75th centiles).
CABG, coronary artery bypass grafting;CGM, continuous glucose monitoring; CVA, cerebral vascular event; DM, diabetes mellitus; FSL-FGM, FreeStyle Libre flash glucose monitoring; OBGLD, oral blood glucose lowering drugs;PCI, percutaneous coronary intervention; T1DM, type I diabetes mellitus; T2DM, type II diabetes mellitus; TIA, transient ischemic attack.